Janet E. Brown

发表

N. James, J. Sherriff, Janet E. Brown, 2010 .

Clinical Outcomes and Survival Following Treatment ofMetastatic Castrate-Refractory Prostate CancerWith Docetaxel AloneorWith Strontium-89 , ZoledronicAcid , or Both The TRAPEZE Randomized Clinical Trial

N. James, L. Billingham, E. Porfiri, 2016 .

OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG‐TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDER‐RECOGNIZED PROBLEM

N. James, J. Sherriff, Janet E. Brown, 2010, BJU international.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry

L. Pickering, E. Porfiri, J. Wagstaff, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).

T. Powles, D. McLaren, S. Crabb, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

M. Sydes, D. Dearnaley, C. Parker, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

N. James, L. Billingham, D. McLaren, 2017, BJU international.

Costeffectiveness of zoledronic acid and strontium89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castraterefractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

S. Beesley, A. Birtle, S. Collins, 2022 .